Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.
Marie-France Savard(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Lynn Huynh(Northern Arizona University), J. Connor Wells(Queen's University), Giovanni Zanotti(Pfizer (United States)), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Frede Donskov(Aarhus University Hospital), Jeffrey Graham(University of Calgary), Bradley A. McGregor(Harvard University), Mei Sheng Duh(Analysis Group (United States)), Ulka N. Vaishampayan(University of Michigan), Marco Iafolla(University of Alberta), Georg A. Bjarnason(Sunnybrook Health Science Centre), Aaron R. Hansen(Princess Margaret Cancer Centre)
Cited by 1
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|Cancer Cell|2021|624
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
|Cancer Cell|2021|528